A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib in Patients with newly diagnosed Philadelphia(Ph) chromosome positive Chronic Myeloid Leukemia in chronic phase.
Not Applicable
Recruiting
- Conditions
- Chronic Myeloid Leukemia
- Registration Number
- JPRN-UMIN000005843
- Lead Sponsor
- Epidemiological and Clinical Research Information Network (ECRIN)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Previous treatment with TKI or IFN-alpha
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A major molecular response(MMR) rate by 12 months after the initiation of Dasatinib treatment
- Secondary Outcome Measures
Name Time Method